BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 27139457)

  • 1. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
    Narayanan S; Colevas AD
    Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 4. Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease.
    Mischler K; Kneifel S; Cathomas R
    Oncol Res Treat; 2016; 39(9):548-52. PubMed ID: 27614988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
    Hegazi M; Azadi A; Jain D; Redman R; Perez CA
    Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapy in Thyroid Cancer: State of the Art.
    Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
    Yeung KT; Cohen EE
    Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer.
    Kirtane K; Roth MY
    Curr Treat Options Oncol; 2020 Feb; 21(3):18. PubMed ID: 32048061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
    Hewett Y; Ghimire S; Farooqi B; Shah BK
    J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
    de la Fouchardiere C; Oussaid N; Derbel O; Decaussin-Petrucci M; Fondrevelle ME; Wang Q; Bringuier PP; Bournaud-Salinas C; Peix JL; Lifante JC; Giraudet AL; Lopez J; Borson-Chazot F
    Target Oncol; 2016 Feb; 11(1):71-82. PubMed ID: 26285789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
    Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
    Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.
    Schmidt A; Iglesias L; Klain M; Pitoia F; Schlumberger MJ
    Arch Endocrinol Metab; 2017; 61(1):81-89. PubMed ID: 28225999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside.
    Abdel-Rahman O
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):45-54. PubMed ID: 25560732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
    Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
    Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
    de la Fouchardiere C; Alghuzlan A; Bardet S; Borget I; Borson Chazot F; Do Cao C; Godbert Y; Leenhardt L; Zerdoud S; Leboulleux S
    Bull Cancer; 2019 Sep; 106(9):812-819. PubMed ID: 31200896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.